Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Titel:
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Auteur:
Molina, Jean-Michel LaMarca, Anthony Andrade-Villanueva, Jaime Clotet, Bonaventura Clumeck, Nathan Liu, Ya-Pei Zhong, Lijie Margot, Nicolas Cheng, Andrew K Chuck, Steven L